Why the new Alzheimer’s drug is eliciting both optimism and caution
Lecanemab targets what some see as the underlying cause of Alzheimer’s, but reports of deaths associated with the treatment have raised concerns.
This content is Subscriber-Exclusive
You must have a National Geographic subscription to explore this article.
